摘要
目的探讨三联方案联合温胃舒胶囊对幽门螺杆菌(Hp)阳性胃溃疡患者血清胃蛋白酶原(PG)及组织三叶因子1(TFF1)水平的影响。方法选取2012年1月至2014年6月于重庆北部新区第一人民医院接受治疗的128例Hp阳性并经胃镜确诊为胃溃疡的患者,根据随机数字表法将患者分为对照组和观察组,每组64例。对照组采用三联疗法(阿莫西林+埃索美拉唑+替硝唑)治疗,观察组在三联疗法基础上联用温胃舒胶囊治疗,两组疗程均为4周。治疗前后采用胃镜观察两组胃溃疡情况,采用ELISA法测定血清PG水平,采用蛋白印迹法测定胃黏膜组织中TFF1蛋白表达水平。结果观察组总有效率为96.88%,复发率为3.12%,对照组总有效率为78.12%,复发率为15.62%,两组间差异具有统计学意义(P<0.05)。观察组和对照组Hp转阴率分别为93.75%和75.00%,两组间差异无统计学意义(P>0.05)。观察组治疗后胃窦及胃体溃疡直径显著小于对照组(P<0.05)。此外,观察组治疗后胃黏膜组织中TFF1蛋白表达水平(P<0.05)及血清PG水平(P<0.01)显著低于对照组。结论三联方案联合温胃舒胶囊可有效改善Hp阳性胃溃疡患者的治疗效果,降低复发率,这可能与温胃舒胶囊能下调PG及TFF1表达水平有关。
Objective To investigate the influence of Wenweishu capsule combined with triple regimen on the serum pepsinogen （PG） and the trefoil factor 1 （TFF1） levels in Helicobacterpylori （Hp） positive patients with gastric ulcer. Methods A total of 128 cases of Hp positive patients with gastric ulcer were divided into control group （n=64） and observation group （n=64）. The control group was treated with triple regimen （amoxicillin, esomeprazole and tinidazole）. The observation group was treated with triple regimen plus Wenweishu capsule, the two groups were treated for 4 weeks. The gastric ulcer situation was observed by endoscopic. The level of serum PG was detected by ELISA and gastric mucosa TFF1 was detected by Western blot. Results The total effective rate and recurrence rate in observation group were 96.88% and 3.12%, and control group were 78.12% and 15.62%, the difference between them was significant （P〈0.05）. The Hp negative rate in observation group and control group was 93.75% and 75.00% respectively, which was no significant difference （P〉0.05）. Both the antrum and body stomach ulcer diameter in observation group were less than control group after treatment （P〈0.05）. The levels of serum PG （P〈0.01） and TFF1 （P〈0.05） in observation group after treatment were significantly lower than in control group. Conclusion The triple regimen plus Wenweishu capsule can improve the treatment efficacy of Hp positive patients with gastric ulcer. The mechanism may be related to that Wenweishu capsule can reduce PG and TFF 1 expression levels.
出处
《世界临床药物》
CAS
2016年第1期42-45,共4页
World Clinical Drug
